Patents by Inventor Raul Mostoslavsky

Raul Mostoslavsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20220152081
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: September 8, 2021
    Publication date: May 19, 2022
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20210030781
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: March 16, 2020
    Publication date: February 4, 2021
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • Agents and methods for treating pancreatic ductal adenocarcinomas
    Patent number: 10588920
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 17, 2020
    Assignee: The General Hospital Corporation
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
    Publication number: 20180085389
    Abstract: It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by con trolling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 29, 2018
    Inventors: Raul Mostoslavsky, Sita Kugel, Anders M. Naar
  • Methods for extending the replicative lifespan of cells
    Patent number: 7838503
    Abstract: The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: November 23, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Frederick W. Alt, David B. Lombard, Katrin F. Chua, Raul Mostoslavsky, Hwei-Ling Cheng
  • Methods for extending the replicative lifespan of cells
    Publication number: 20070160586
    Abstract: The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.
    Type: Application
    Filed: June 14, 2006
    Publication date: July 12, 2007
    Applicant: Children's Medical Center Corporation
    Inventors: Frederick Alt, David Lombard, Katrin Chua, Raul Mostoslavsky, Hwei-Ling Cheng
  • SIRT6 transgenic non-human animals and assay methods
    Publication number: 20050204410
    Abstract: Assay methods for identifying agents capable of modulating SIRT6 activity or expression, as well as non-human transgenic animals useful for identifying agents capable of inhibiting aging-associated degenerative processes.
    Type: Application
    Filed: March 11, 2005
    Publication date: September 15, 2005
    Inventors: Margaret Karow, Raul Mostoslavsky, Frederick Alt